thermo fisher result commentari suggest mix
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim
price data apr
rate updat apr
currenc amount express
methodolog valu compani
thermo fisher first-quart result forward-look
commentari provid clariti remain
uncertain environ compani industri
whole expect thermo fisher one
healthcar compani see modest benefit
epidem given posit one supplier rapid
diagnost viru albeit revenu boost
diagnost segment larg off-set materi pullback
analyt instrument tend quit poorli
recession environ still make
adjust model follow quarter
recent updat forecast attempt handicap
impact far compani commentari
expect chang fair valu estim
quarter asid last week larg
shield
meaning except china thermo fisher saw
demand collaps earlier quarter result
revenu declin demand gradual return
level activ region current
normal second quarter howev feel full
brunt epidem surprisingli forecast
revenu declin rang absurdli larg -- flat growth
neg upper end would impli materi
uptak compani test thermo
fisher produc million per week pace pace
recoveri also major variabl given compani
product mix larg consum anticip thermo
fisher return normalci faster healthcar
firm epidem might actual lead market share
gain acceler revenu growth beyond
thermo fisher anticip direct tailwind
million revenu second quarter
upper rang would impli demand diagnost
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
thermo fisher scientif sell scientif instrument laboratori
equip diagnost consum life scienc reagent firm
includ
cross-seg revenu analyt technolog sale specialti
diagnost product life scienc solut lab product
servic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
would eventu reach possibl exceed million
per week suppli seem bit stretch although
tailwind directli link test
anticip headwind neg view
lower-end like scenario either compani
pharma channel larg unaffect epidem
drug develop manufactur seen
materi pullback activ academ govern
demand bit fickl vari base
univers resum research activ
except industri end market anticip
sooner rather later recoveri
thermo fisher differ compani versu one
back use recess benchmark
valuabl firm exposur industri
cyclic end market materi lower mix instrument
versu consum tilt substanti toward
latter pharma channel much larger end
market fairli immun econom recess
surprisingli thermo share see kind
sell-off experienc mani medic technolog firm
market appear price defens natur
busi opportun may
diagnost segment consid share
attract valu
compani pend acquisit proceed
plan thermo fisher commenc rais capit
fund transact debt issu quarter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
